Goldman Sachs Downgrades Vertex (VRTX) to Neutral

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 9/9/2026

1. BRZE
2. TTAN
3. AAPL
4. CHYM
5. USO
6. IRT
7. QCOM
8. ASO
9. LAES
10. UNFI

Go back to Goldman Sachs Downgrades Vertex (VRTX) to Neutral

Vertex Pharma (VRTX) Sees Red-to-Green Reversal Following EPS

April 28, 2016 10:27 AM EDT

Vertex Pharma (NASDAQ: VRTX) reverse sharply off morning lows following earning after the close, which were seen as lackluster.

Shares are currently up 1% after opening down 3.9%.

... More

Vertex (VRTX) PT, Estimates Cut at Baird

April 28, 2016 7:45 AM EDT

Baird analyst Brian Skorney lowered his price target on Vertex (NASDAQ: VRTX) to $128.00 (from $144.00) and Orkambi estimates on weak qua but maintained an Outperform rating.

Skorney commented, "Orkambi sales came in well below expectations that had already been revised significantly downwards over the last... More

Vertex Pharma (VRTX) Misses Q1 EPS by 20c; Increases 2016 KALYDECO Revenue Guidance

April 27, 2016 4:03 PM EDT

Vertex Pharma (NASDAQ: VRTX) reported Q1 EPS of $0.09, $0.20 worse than the analyst estimate of $0.29. Revenue for the quarter came in at $398.1 million versus the consensus estimate of $439.36 million.

First quarter 2016 cystic fibrosis product revenues of $394 million; $223 million for ORKAMBI® (lumacaftor/ivacaftor) and $171 million for KALYDECO®... More